Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using our innovative receptor technology to identify and develop drugs in areas with an unmet need.
Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with Kidney Disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Dimerix comprises 2 distinct entities:
- Dimerix Limited (ASX:DXB)
- Dimerix Biosciences Pty Ltd (a wholly owned subsidiary of Dimerix Limited)